.jpg?format=webp&width=780)
In a study, osimertinib, a potent third-generation EGFR-TKI, combined with chemotherapy, shows remarkable efficacy in treating advanced EGFRm NSCLC. The study, with 557 patients, revealed a significant progression-free survival benefit over osimertinib monotherapy (median improvement of 8.8 months). The overall response rate was 83% vs. 76%, demonstrating the combo's superiority. While comprehensive survival data is still immature, the manageable safety profile underscores osimertinib plus chemotherapy as a promising first-line treatment for EGFRm NSCLC.
Like
Save
Share